However, following the increase in usage of EGFR-TKIs in lung cancer therapy, a significantly higher incidence of life-threatening drug induced ILD in Japanese patients than that of patients in the rest of the world was reported [38,39]. The gene discussed is EGFR; the disease is interstitial lung disease.